Canaccord Genuity Maintains Buy on Tango Therapeutics, Raises Price Target to $46

Benzinga Newsdesk www.benzinga.com Positive 83.7%

Neg 0% Neu 0% Pos 83.7%

Canaccord Genuity analyst John Newman maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $42 to $46.